BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 32062650)

  • 21. Efficacy of Vonoprazan for 48-Week Maintenance Therapy of Patients with Healed Reflux Esophagitis.
    Mizuno H; Nishino M; Yamada K; Kamiyamamoto S; Hinoue Y
    Digestion; 2020; 101(4):411-421. PubMed ID: 31129668
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Positive predictors for gastroesophageal reflux disease and the therapeutic response to proton-pump inhibitors.
    Becker V; Grotz S; Schlag C; Nennstiel S; Beitz A; Haller B; Schmid RM; Meining A; Bajbouj M
    World J Gastroenterol; 2014 Apr; 20(14):4017-24. PubMed ID: 24744591
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combined pH-impedance monitoring and high-resolution manometry of Japanese patients treated with proton-pump inhibitors for persistent symptoms of non-erosive reflux disease.
    Yamashita H; Ashida K; Fukuchi T; Nagatani Y; Koga H; Senda K; Eguchi T; Ubukata S; Kawaguchi S; Ueda A; Tanaka T; Ohashi R; Ito D
    J Smooth Muscle Res; 2012; 48(5-6):125-35. PubMed ID: 23538509
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tailored therapy for the refractory GERD patients by combined multichannel intraluminal impedance-pH monitoring.
    Xiao Y; Liang M; Peng S; Zhang N; Chen M
    J Gastroenterol Hepatol; 2016 Feb; 31(2):350-4. PubMed ID: 26202002
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of gastroesophageal reflux in relation to symptom onset in patients with proton pump inhibitor-refractory nonerosive reflux disease accompanied by an underlying esophageal motor disorder.
    Izawa S; Funaki Y; Iida A; Tokudome K; Tamura Y; Ogasawara N; Sasaki M; Kasugai K
    Digestion; 2014; 89(1):61-7. PubMed ID: 24458115
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adding Acotiamide to Gastric Acid Inhibitors Is Effective for Treating Refractory Symptoms in Patients with Non-erosive Reflux Disease.
    Yamashita H; Okada A; Naora K; Hongoh M; Kinoshita Y
    Dig Dis Sci; 2019 Mar; 64(3):823-831. PubMed ID: 30465175
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Diagnostic Utility of Impedance-pH Monitoring in Refractory Non-erosive Reflux Disease.
    Khan MQ; Alaraj A; Alsohaibani F; Al-Kahtani K; Jbarah S; Al-Ashgar H
    J Neurogastroenterol Motil; 2014 Oct; 20(4):497-505. PubMed ID: 25273120
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clinical utility of salivary pepsin measurement in patients with proton pump inhibitor-refractory gastroesophageal reflux disease symptoms: a prospective comparative study.
    Matsumura T; Arai M; Suzuki T; Hoppo T; Seki Y; Kasamatsu S; Ishigami H; Ishikawa K; Okimoto K; Akizue N; Maruoka D; Nakagawa T; Odaka T; Okamoto Y; Kato N
    Esophagus; 2020 Jul; 17(3):339-347. PubMed ID: 31982992
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of proton pump inhibitor-resistant nonerosive reflux disease by esophageal manometry and 24-hour esophageal impedance and pH monitoring.
    Kawamura O; Hosaka H; Shimoyama Y; Kawada A; Kuribayashi S; Kusano M; Yamada M
    Digestion; 2015; 91(1):19-25. PubMed ID: 25632912
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pathogenesis of Double-Dose Proton Pump Inhibitor-Resistant Non-Erosive Reflux Disease, and Mechanism of Reflux Symptoms and Gastric Acid Secretion-Suppressive Effect in the Presence or Absence of Helicobacter pylori Infection.
    Kawami N; Takenouchi N; Umezawa M; Hoshino S; Hanada Y; Hoshikawa Y; Sano H; Hoshihara Y; Nomura T; Uchida E; Iwakiri K
    Digestion; 2017; 95(2):140-145. PubMed ID: 28161707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pathophysiology of Potassium-competitive Acid Blocker-refractory Gastroesophageal Reflux and the Potential of Potassium-competitive Acid Blocker Test.
    Masaoka T; Kameyama H; Yamane T; Yamamoto Y; Takeuchi H; Suzuki H; Kitagawa Y; Kanai T
    J Neurogastroenterol Motil; 2018 Oct; 24(4):577-583. PubMed ID: 30347936
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acid and non-acid reflux in patients with persistent symptoms despite acid suppressive therapy: a multicentre study using combined ambulatory impedance-pH monitoring.
    Mainie I; Tutuian R; Shay S; Vela M; Zhang X; Sifrim D; Castell DO
    Gut; 2006 Oct; 55(10):1398-402. PubMed ID: 16556669
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Multichannel intraluminal impedance in the evaluation of patients with persistent globus on proton pump inhibitor therapy.
    Anandasabapathy S; Jaffin BW
    Ann Otol Rhinol Laryngol; 2006 Aug; 115(8):563-70. PubMed ID: 16944654
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Twice-daily proton pump inhibitor therapy does not decrease the frequency of reflux episodes during nocturnal recumbency in patients with refractory GERD: analysis of 200 patients using multichannel intraluminal impedance-pH testing.
    Clayton SB; Rife CC; Singh ER; Kalbfleisch JH; Castell DO
    Dis Esophagus; 2012; 25(8):682-6. PubMed ID: 22292567
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characteristics of symptomatic reflux episodes in patients with non-erosive reflux disease who have a positive symptom index on proton pump inhibitor therapy.
    Iwakiri K; Sano H; Tanaka Y; Kawami N; Umezawa M; Futagami S; Hoshihara Y; Nomura T; Miyashita M; Sakamoto C
    Digestion; 2010; 82(3):156-61. PubMed ID: 20588027
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy of Vonoprazan for Refractory Reflux Esophagitis after Esophagectomy.
    Ochiai Y; Iizuka T; Hoshihara Y; Suzuki Y; Hayasaka J; Nomura K; Tanaka M; Odagiri H; Yamashita S; Matsui A; Kikuchi D; Ueno M; Udagawa H; Hoteya S
    Dig Dis; 2021; 39(6):569-576. PubMed ID: 33567428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Esophageal pH-impedance monitoring in patients with therapy-resistant reflux symptoms: 'on' or 'off' proton pump inhibitor?
    Hemmink GJ; Bredenoord AJ; Weusten BL; Monkelbaan JF; Timmer R; Smout AJ
    Am J Gastroenterol; 2008 Oct; 103(10):2446-53. PubMed ID: 18684197
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Short-Term Symptomatic Relief in Gastroesophageal Reflux Disease: A Comparative Study of Esomeprazole and Vonoprazan.
    Sakurai K; Suda H; Fujie S; Takeichi T; Okuda A; Murao T; Hasuda K; Hirano M; Ito K; Tsuruta K; Hattori M
    Dig Dis Sci; 2019 Mar; 64(3):815-822. PubMed ID: 30415407
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus.
    Emerenziani S; Sifrim D; Habib FI; Ribolsi M; Guarino MP; Rizzi M; Caviglia R; Petitti T; Cicala M
    Gut; 2008 Apr; 57(4):443-7. PubMed ID: 17766596
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Multichannel intraluminal impedance-pH testing is clinically useful in the management of patients with gastroesophageal reflux symptoms.
    Jodorkovsky D; Price JC; Kim B; Dhalla S; Stein EM; Clarke JO
    Dig Dis Sci; 2014 Aug; 59(8):1817-22. PubMed ID: 24563276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.